Yetkin Tuaç

Dr. Yetkin Tuaç

Statistics, Ankara University, Ankara, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

18 July 2017 in Communications in Statistics - Simulation and Computation
Verified
Journal Article
Closed access
Yetkin TuaçYetkin Tuaç
Yetkin Tuaç
YGY. Güney
Y. Güney
BŞB. Şenoğlu
B. Şenoğlu
OAO. Arslan
O. Arslan
In this article, we consider a linear regression model with AR(p) error terms with the assumption that the error terms have a t distribution as a heavy-tailed alternative to the normal distribution. We obtain the estimators for the model parameters by using the conditional maximum likelihood (CML) method. We conduct an iteratively reweighting algorithm (IRA) to find the estimates for the parameters of interest. We provide a simulation study and three real data examples to illustrate the performance of the proposed robust estimators based on t distribution.

23 June 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
MYMelis Keskin Yıldız
Melis Keskin Yıldız
YKYusuf Kemal Kemaloğlu
Yusuf Kemal Kemaloğlu
Yetkin TuaçYetkin Tuaç
Yetkin Tuaç
GMGüven Mengü
Güven Mengü
RKRecep Karamert
Recep Karamert
ÇGÇağıl Gökdoğan
Çağıl Gökdoğan
Aim Subjective noise sensitivity (SNS) is not only one of the most important predictors of perceived noise annoyance for the subjects exposed to the noise, but also strongly related with some psychological conditions and poor health perception of the subjects. The Weinstein?s Noise Sensitivity Scale (WNSS) is widely used for measuring of SNS. Materials and Methods In this study we adapted WNSS to Turkish (Tr-WNSS) and evaluated its psychometric properties and effect of age, sex and education level on SNS. Results The study included 105 males and 105 female subjects between 18 and 55 years of age. Conclusion Our data demonstrated that Tr-WNSS was a reliable, valid, and invariant scale for Turkish population, and not affected by sex, age and education level.

1 July 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
MSMutlay Sayan
Mutlay Sayan
AEAyfer Ay Eren
Ayfer Ay Eren
Yetkin TuaçYetkin Tuaç
Yetkin Tuaç
ALAstrid Langoe
Astrid Langoe
BABader Alali
Bader Alali
MEmehmet eren
mehmet eren
PURPOSE: Prostate cancer has emerged as a significant public health challenge in the Middle East, characterized by rising incidence rates and a concerning mortality-to-incidence ratio. Yet, despite these alarming trends, data regarding prostate cancer awareness in the region remain limited. To address this critical knowledge gap, this study investigates prostate cancer awareness within the Middle East. MATERIALS AND METHODS: A cross-sectional survey was performed among 5,913 men age 40 years and older across 14 Middle Eastern countries between January 1, 2022, and July 31, 2023. Excluding those with a history of prostate cancer, a validated questionnaire assessed prostate cancer awareness. Data were analyzed using frequencies and percentages for categorical variables, medians and ranges for continuous variables, and Pearson chi-square analysis for relationships between education levels and awareness of prostate cancer. RESULTS: The survey achieved a 74.9% response rate, with 4,431 male participants. Regarding prostate cancer awareness, 83.8% of participants had heard of the disease. However, only 31.0% correctly identified it as the most common malignancy in men, and 21.8% believed it affects both sex. Awareness of screening was limited, with just 19.1% recognizing the prostate-specific antigen test's role. Additionally, participants had a pessimistic view, with a mean perception that 75% of patients with prostate cancer die from the disease, rather than from other causes. Higher education levels were associated with significantly increased awareness of prostate cancer ( P < .001). CONCLUSION: This study reveals that while general awareness of the disease exists, crucial knowledge deficits regarding risk factors, screening, and prognosis are evident. Addressing these knowledge gaps through culturally tailored education may improve early detection rates, treatment outcomes, and ultimately reduce the burden of prostate cancer in the Middle East.

22 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MSMutlay Sayan
Mutlay Sayan
Yetkin TuaçYetkin Tuaç
Yetkin Tuaç
MAMahmut Akgul
Mahmut Akgul
GPGrace Pratt
Grace Pratt
MRMary D. Rowan
Mary D. Rowan
CACagdas AKTAN
Cagdas AKTAN
Purpose: Given the diverse clinical progression of prostate cancer (PC) and the evolving significance of histopathological factors in its management, this study aimed to explore the impact of cribriform pattern 4 (CP4) on clinical outcomes in PC patients and examine its molecular characteristics. Methods: This retrospective study analyzed data from The Cancer Genome Atlas (TCGA) database and included PC patients who underwent radical prostatectomy (RP) and had pathology slides available for the assessment of CP4. A multivariable competing risk regression analysis was used to assess the association between CP4 and progression-free survival (PFS) while adjusting for established PC prognostic factors. The frequency of genomic alterations was compared between patients with and without CP4 using the Fisher’s exact test. Results: Among the 394 patients analyzed, 129 (32.74%) had CP4. After a median follow-up of 40.50 months (IQR: 23.90, 65.60), the presence of CP4 was significantly associated with lower PFS (AHR, 1.84; 95% CI, 1.08 to 3.114; p = 0.023) after adjusting for covariates. Seven hub genes—KRT13, KRT5, KRT15, COL17A1, KRT14, KRT16, and TP63—had significantly lower mRNA expression levels in patients with CP4 compared to those without. Conclusions: PC patients with CP4 have distinct genomic alterations and are at a high risk of disease progression following RP. Therefore, these patients may benefit from additional post-RP treatments and should be the subject of a prospective randomized clinical trial.